Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on the next generation of obesity and cardiometabolic care through a diversified pipeline of GLP-1 based therapies. Founded in 2024 and headquartered in Waltham, Massachusetts, its lead candidate ribupatide (KAI-9531) is a once-weekly injectable GLP-1/GIP receptor dual agonist in a global Phase 3 program, alongside oral small-molecule GLP-1 candidates and tri-agonist programs licensed in part from Jiangsu Hengrui Pharmaceuticals. Kailera has raised a $400M Series A and a $600M Series B led by Bain Capital, and priced its IPO in April 2026 (NASDAQ: KLRA). This is a corporate/portfolio company profile in the API Evangelist network; Kailera publishes no public developer API surface.

Kailera Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Biotechnology, Pharmaceuticals, and Obesity.

Kailera Therapeutics’ developer surface includes engineering blog, support, and 7 more developer resources.

🌐 Visit website 📡 Source on GitHub

15.0/100 emerging ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiopharmaceuticalBiotechnologyPharmaceuticalsObesityMetabolic HealthGLP-1Clinical StageHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 15.0/100 · emerging

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/kailera-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 5

The organization behind the API

Website

Website

About

About

Blog

Blog

LinkedIn

Twitter

Twitter

Source (apis.yml)

aid: kailera-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/kailera-therapeutics.png
name: Kailera Therapeutics
description: 'Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on the next generation of obesity
  and cardiometabolic care through a diversified pipeline of GLP-1 based therapies. Founded in 2024 and headquartered in Waltham,
  Massachusetts, its lead candidate ribupatide (KAI-9531) is a once-weekly injectable GLP-1/GIP receptor dual agonist in a
  global Phase 3 program, alongside oral small-molecule GLP-1 candidates and tri-agonist programs licensed in part from Jiangsu
  Hengrui Pharmaceuticals. Kailera has raised a $400M Series A and a $600M Series B led by Bain Capital, and priced its IPO
  in April 2026 (NASDAQ: KLRA). This is a corporate/portfolio company profile in the API Evangelist network; Kailera publishes
  no public developer API surface.'
url: https://raw.githubusercontent.com/api-evangelist/kailera-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
- Bain Capital
- Atlas Venture
- RTW Investments
x-tier: profile
x-tier-reason: no-public-api
x-ticker: KLRA
x-headquarters: Waltham, Massachusetts, United States
x-founded: '2024'
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biopharmaceutical
- Biotechnology
- Pharmaceuticals
- Obesity
- Metabolic Health
- GLP-1
- Clinical Stage
- Healthcare
apis: []
common:
- type: DomainSecurity
  url: security/kailera-therapeutics-domain-security.yml
- type: Website
  url: https://www.kailera.com/
- type: About
  url: https://www.kailera.com/about-us/
- type: Blog
  url: https://investors.kailera.com/news-events/news-releases
- type: Support
  url: https://www.kailera.com/contact-us/
- type: PrivacyPolicy
  url: https://www.kailera.com/kailera-privacy-policy/
- type: TermsOfService
  url: https://www.kailera.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/kaileratx/
- type: Twitter
  url: https://x.com/kaileratx
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence